NCT06386705View on ClinicalTrials.gov

TSN084 Treating Patients With Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Malignant Neoplasm
Interventions
DRUG

TSN084

TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Trial Locations (2)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

100142

RECRUITING

Peking university cancer hospital, Beijing

All Listed Sponsors
lead

Tyligand Bioscience (Shanghai) Limited

INDUSTRY